These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19779026)

  • 1. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation.
    Padol IT; Hunt RH
    Rheumatology (Oxford); 2010 May; 49(5):837-43. PubMed ID: 19779026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.
    Abraham NS; El-Serag HB; Hartman C; Richardson P; Deswal A
    Aliment Pharmacol Ther; 2007 Apr; 25(8):913-24. PubMed ID: 17402995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacology of selective inhibition of COX-2.
    Grosser T
    Thromb Haemost; 2006 Oct; 96(4):393-400. PubMed ID: 17003913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
    Amer M; Bead VR; Bathon J; Blumenthal RS; Edwards DN
    Cardiol Rev; 2010; 18(4):204-12. PubMed ID: 20539104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis?
    Lo V; Meadows SE; Saseen J
    J Fam Pract; 2006 Mar; 55(3):260-2. PubMed ID: 16510063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis].
    Stańczyk J; Kowalski ML
    Pol Merkur Lekarski; 2001 Nov; 11(65):438-43. PubMed ID: 11852819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population.
    García Rodríguez LA; Tacconelli S; Patrignani P
    J Am Coll Cardiol; 2008 Nov; 52(20):1628-36. PubMed ID: 18992652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoarthritis therapy--are there still unmet needs?
    Laufer S
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?
    Aneja A; Farkouh ME
    Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):53-66. PubMed ID: 19124408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
    Lee MC; Lee S; Suh DC; Kim J; Kong SX;
    Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of anti-inflammatory treatment--new ways of thinking.
    Brune K
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.